Media contacts:
Janet Christenbury, 404/727-8599,
Kathi Ovnic, 404/727-9371,
May 30, 2002


Emory Researchers Seek Patients with Osteoarthritis for Drug Study

Emory University researchers are recruiting African American patients with osteoarthritis of the knee for a study involving a new COX-2 inhibitor, a drug targeted at reducing arthritis pain, inflammation and stiffness. Researchers are trying to determine if the newly marketed drug works as well in African Americans as in the general population. Osteoarthritis is described as the degenerative wear and tear of the bone and cartilage in one or more joints.

"African Americans generally have a different pattern of osteoarthritis," says J. Robin DeAndrade, M.D., professor of orthopaedics at Emory and lead investigator of this study. "Their bone structure is much more dense than other populations. So we want to see how effective this COX-2 inhibitor will be in helping to relieve their pain and inflammation."

To enroll, participants must have osteoarthritis of the knee, be 45 years of age and older and must not have undergone knee replacement surgery. Participants in the trial will be selected randomly to receive the study drug, another older and more standard drug used for years to treat osteoarthritis, or a placebo.

Four office visits over a six-week period are required to participate in the study. Medication and office visits are provided free of charge. A small stipend for reimbursement of travel will be given to participants. The drug company that manufactures this new COX-2 inhibitor is funding this multi-center trial. Eligible participants or individuals seeking more information about the study can call (404) 778-6370.

Return to May Index

For more general information on The Robert W. Woodruff Health Sciences Center
call Health Sciences Communication's Office at 404-727-5686,
or send e-mail to

Copyright © Emory University, 2001. All Rights Reserved.